This week, a Spanish town did not actually hold a clitoris festival, an economic analysis fears that as global temperatures rise our sex lives (and birth rates) will suffer, and new research suggests veterans suffer from sexual dysfunction.
A new drug promising to help women restore lost libido has been approved by the FDA. But is it just a bill of goods? And does the marketing of this actually hurt the cause of women’s sexual freedom?
The pharmaceutical industry launched a campaign in January of this year to persuade the FDA to approve such medications in the name of equality—which overlooks the fact that most of the drugs being considered simply don’t work.
One writer calls them “panty-dropping pills” while advocates and feminists have already lined up to fight any sort of FDA approval. Flibanserin is being reported as a “female Viagra” but it’s not lived up to the job of alleviating symptoms of low sexual desire in women. Why?
A review of the film Orgasm, Inc. about the medicalization of female sexual pleasure in the US and a look into what female sexual dysfunction is and who benefits.